Briefly, the aggressive breast cancer tumors secrete TβRII-enriched EVs and stimulate TGF-β/SMAD activation in adjacent pre-malignant tumor cells and remote recipient such as CD8+ T cells. This evidence concerns the gene CD8A and breast carcinoma.